top of page

Search


Systemic Gaps Hinder Cell and Gene Therapy Adoption and Access
espite the transformative potential of cell and gene therapies, widespread adoption remains limited due to systemic gaps in infrastructure, reimbursement models, and coordination of care.
May 12


Cardinal Health: 2025 Advanced Therapies Report
In this report, you’ll learn from experts commenting on key challenges and emerging solutions within this space, including how cell gene therapies are revolutionizing patient care while creating new challenges for us as an industry.
May 9


Specialty Drugs Dominate Pharmaceutical Frontier in 2025
In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.
Apr 15


US Pharmaceutical Pipeline Expands With Innovation and Competition
A surge of generics, biosimilars, and innovative therapies are expected in 2025, addressing conditions from cancer to chronic diseases.
Apr 8


Nonopioid Pain Drug Journavx Gaining Traction With High Potential
Journavx is seeing strong initial market adoption, with growing payer coverage and ongoing clinical studies aimed at expanding its use
Mar 25


The Biosimilars Report Card
It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are...
Mar 5


IPD Analytics Becomes Networking Partner for Annual Pharma IPR India Conference
IPD Analytics joins as Networking partner for the 14th Annual Pharma IPR India Conference
Feb 6


FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
Jan 31


Trump Impact on Medicare Drug Price Negotiations Uncertain
Trump has reversed some of President Biden’s initiatives, but so far the healthcare elements of the Inflation Reduction Act remain unchanged
Jan 22


ICYMI: Highlights From AMCP Nexus 2024
Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting.
Dec 26, 2024


Trends and Transformation: Gene Therapies in Rare Blood Disorders
Gene therapies for rare blood disorders show promise with reduced crises and improved life quality, despite high costs and slow adoption.
Dec 24, 2024


Harnessing the Potential of CAR T-Cell Therapy for Multiple Myeloma
CAR T-cell therapy offers hope for multiple myeloma, showing efficacy in trials but challenges in antigen targeting and tumor infiltration.
Dec 15, 2024


StockWatch: ARK Mostly Bullish on CRISPR Therapeutics
CRISPR Therapeutics faces challenges despite FDA approval for a breakthrough therapy, with slow progress impacting stock performance.
Dec 6, 2024


Expanding Access to Gene Therapies: Addressing Patient Burden, High Costs
Gene therapies are very labor intensive, so despite their life-saving potential, access to and utilization of these therapies is a challenge
Dec 3, 2024


Can Global Policies Boost Biosimilar Adoption Work in the US?
On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...
Nov 17, 2024


Why Haven't More Patients Been Treated With the Gene Therapies for Sickle Cell Disease? | AMCP Nexus 2024
Uncover the reasons behind the limited adoption of gene therapies for sickle cell disease at the AMCP Nexus 2024.
Oct 15, 2024


Can Outcomes-Based Agreements Work for Weight Loss Drugs?
Outcomes-based agreements can take away clinical uncertainties, so payers have a guarantee that they're not spending money on something...
Sep 4, 2024


Upcoming Biosimilars and the Impact of IRA: Key Takeaways From Jeffrey Casberg
Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and...
Sep 3, 2024


Biosimilars in America: Overcoming Barriers and Maximizing Impact
issues affecting payer uptake and provider adoption of biosimilars in the US, such as economic considerations, clinical evidence, and market
Jul 21, 2024


IPD Analytics' Jeffrey Casberg Discusses Recent Biosimilar Approvals
Jeffrey Casberg, MS, RPh, senior vice president of pharmacy at IPD Analytics, discussed the FDA approvals of new drugs and pricing.
Jul 14, 2024
bottom of page